Safeguard Scientifics Inc 8-K, filed May 27, 2022
Safeguard Scientifics Inc (SFES)
8-K
2022-05-27
For: 2022-05-25
View Original
Added on
April 06, 2026
About this 8-K
Safeguard Scientifics Inc filed this 8-K on May 27, 2022, reporting on events of May 25, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 25, 2022
(Exact Name of registrant as Specified in Charter)
|
|
|
|
|
(State or other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer ID No.)
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: 610 -293-0600
Not applicable
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
On May 25, 2022, at the annual meeting of shareholders (the “Annual Meeting”) of Safeguard Scientifics, Inc. (the “Company”), Ross D. DeMont and Beth S. Michelson were elected as directors of the Company, to serve until the Company’s 2023 annual meeting of shareholders and until a successor is elected and qualified.
Mr. DeMont will serve on the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Company’s Board of Directors. Mr. DeMont will also serve as the Chairman of the Compensation Committee.
Ms. Michelson will serve on the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Company’s Board of Directors.
Mr. DeMont is currently Chief Investment Officer at the Rainin Group, Inc., which manages the assets of both a family office and the investments of the Kenneth Rainin Foundation. Previously, Mr. DeMont was a Managing Member and Portfolio Manager of Midwood Capital Management, a private investment partnership making concentrated investments in public companies. Before this role, Mr. DeMont was an Associate at Igoe Capital Partners, a hybrid public/private equity investment firm with a primary focus on the small- and micro-cap sectors. Mr. DeMont also worked at Presidio strategies in Mergers and Acquisitions and JP Morgan with a focus on Corporate Finance and Mergers and Acquisitions. He previously served on multiple Boards of Directors, including Desalitech and Sierra Monitor Corp.
Ms. Michelson is a private equity investor with more than two decades of building businesses globally. In addition to having served on audit and compensation committees, Ms. Michelson is also a Chartered Financial Analyst and has structured and deployed over $500 million of investment capital. Ms. Michelson is currently a Senior Managing Director at Cartesian Capital, a growth oriented private equity firm and is on the management team of two SPACS, Cartesian Growth Corporation I and II, where she serves as CFO and Director.
Each of Mr. DeMont and Ms. Michelson will receive compensation for their services as a director of the Company based on the Company’s general Board compensation policies as reported in the Company’s definitive proxy statement on Schedule 14A in the section entitled “Corporate Governance and Board Matters – Board Compensation,” which was filed with the Securities and Exchange Commission on April 5, 2022.
There are no arrangements or understandings between Mr. DeMont and any other persons pursuant to which Mr. DeMont was selected as a director. There are no arrangements or understandings between Ms. Michelson and any other persons pursuant to which Ms. Michelson was selected as a director. There are no transactions involving Mr. DeMont or Ms. Michelson required to be disclosed pursuant to Item 404(a) of Regulation S-K.
| ITEM 5.07. | Submission of Matters to a Vote of Security Holders. |
The Annual Meeting of the Company was held on May 25, 2022. As of the Record Date of March 23, 2022, there were 16,627,302 shares of common stock outstanding and entitled to notice of, and to vote at, the Annual Meeting. The matters voted upon at the Annual Meeting and the results of the voting are set forth below.
2
Proposal I – Election of Directors
Shareholders approved the election of five directors to serve as directors for a one-year term to expire at the 2023 Annual Meeting. The voting results for this proposal are as follows:
|
Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Ross D. DeMont
|
9,987,197
|
226,680
|
3,172,239
|
|
Russell D. Glass
|
8,068,620
|
1,595,257
|
3,722,239
|
|
Joseph M. Manko, Jr.
|
8,977,892
|
1,235,985
|
3,172,239
|
|
Beth S. Michelson
|
8,485,852
|
1,178,025
|
3,722,239
|
|
Maureen F. Morrison
|
8,271,645
|
1,392,232
|
3,722,239
|
Proposal II – Advisory Vote Concerning Executive Compensation of the Named Executive Officers
Shareholders approved, on an advisory basis, the Company’s compensation of its named executive officers, as disclosed in the Compensation Discussion and Analysis and Executive Compensation sections of the Company’s 2022 Annual Meeting Proxy Statement. The voting results for this proposal are as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes |
| 7,916,204 | 1,815,354 | 152,319 | 3,502,239 |
Proposal III– Ratification of the Appointment of Grant Thornton LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2022
Shareholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for its 2022 fiscal year. The voting results for this proposal are as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes | |
| 12,645,564 | 270,747 | 141,038 | 328,767 |
|
ITEM 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL).
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Safeguard Scientifics, Inc.
|
|||
|
Date: May 27, 2022
|
By:
|
/s/ G. Matthew Barnard
|
|
|
Name: G. Matthew Barnard
|
|||
|
Title: General Counsel
|
|||
4